VIENNA, Austria, April 25, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today presented two late breaker posters at the 50th Annual Meeting of the European Association for the Study of the Liver (EASL) during The International Liver Congress 2015.
"We believe that the ability to achieve 100% SVR12 after six-weeks of treatment with ACH-3102 and sofosbuvir supports the potential for our proprietary doublet regimen to reduce treatment duration for HCV patients," commented Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion. "We are also very pleased with the robust Phase 1 proof-of-concept data reported on ACH-3422, our proprietary NS5B nucleotide polymerase inhibitor, and the clinical virology presentation that continues to support the differentiated higher barrier to resistance for ACH-3102.
They want options $6 to expire worthless ?
April 7, 2015 Healthcare 0 Comments
Cytori Therap. Receives a Buy from Roth Capital
By Corrie Williams
Roth Capital analyst Joseph Pantginis maintained a Buy rating on Cytori Therap. yesterday and set a price target of $6. The company’s shares closed yesterday at $1.32.
Cytori Therap. has an analyst consensus of Strong Buy, with a price target consensus of $6.50.
The company has a one year high of $2.63 and a one year low of $0.36. Currently, Cytori Therap. has an average volume of 4.64M.
Financial bloggers on sites such as SeekingAlpha and others, seem to have Positive view on CYTX. When evaluating the opinions of financial bloggers over the last 3 months, 50% of bloggers have indicated a Bullish sentiment, while 50% have indicated a Bearish sentiment.
and $7 call expire worthless.
These thiefs are @ work with options every day every week
This is the method 99.9% of insiders for ALL COMPANIES pay the taxes due on stock options.
My question is why do shorts try to infer that this is bad ?
This is the SMART / INTELLIGENT method used to pay taxes due, I guess smart and intelligent are
attributes SHORTS do not possess
P/E 13 , pays dividend , these a whole analyst should be going after unprofitable companies.
thats the firm your dealing with.
to achieve some financial gain at the EXPENSE of RETAIL shareholders. that is less than honest.
Absolutely no reason for any firm to issue any opinion until Himax reports the QTR. Then issue a report based on FACTS not some concocted opinion .